Medical Products Supplies Companies

Uerdinger Str. 3, 47441 Moers
Germany
Telephone +49 2841 8890470
Fax +49 2841 8890472
info@mediwiss-analytic.de
http://www.mediwiss-analytic.de

Product Categories

Product categories

03 Diagnostic Tests
03.02 Immunochemistry testing, immunology testing
03.02.01 Immuno assay testing

Immuno assay testing

Our products

Product category: Immuno assay testing
AllergyScreen®
The AllergyScreen® test is an immunoblot assay for the quantitative determination of circulating allergen-specific Immunoglobulin E (IgE) in human serum with up to 20 allergens per test.

The advantage over determinations with single systems is the simple analysis of a whole range of allergens in one operation, whereby only 250 µl of serum are necessary for 20 allergens, within 2.5 hours.

The results are printend out in iU/ml (range 0.35 – 100 iU/ml) as well as in classes (1-6). In this way, an efficient and economic determination of specific IgE is given compared to a single test system.

For AllergyScreen®, there are various set membranes and customizable membranes available with up to 20 allergens per test.

Product category: Immuno assay testing
AlleisaScreen®
The AlleisaScreen® is an immunoblot assay for the quantitative determination of circulating allergen-specific Immunoglobulin E (IgE) in human serum with up to 30, 44 or 60 allergens per test.

The advantage over determinations with single allergen test systems is the simple analysis of a whole range of allergens in one operation within 2.5 hours, whereby only 300 µl for 30 allergens or 600 µl for 44 and 60 allergens of serum are required.

The results are printed out in iU/ml (range 0.35 – 100 iU/ml) as well as in classes (1-6). In this way, an efficient and economic determination of specific IgE is given compared to a single allergen test system.

Product category: Immuno assay testing
CCD-Blocking-Solution
A convenient feature in the
AlleisaScreen® system
Many allergens are glycoproteins, which consist of a protein part and one or more glycan chains. Glycan chains are composed of different sugars linked together and are bound via an amino-group (N-glycan) or a hydroxyl-group (O-glycan) to the protein part. N-glycans are particularly immunogenic and can induce the production of IgE, specific for N-glycans, which are usually pathologically irrelevant.

These IgE antibodies are highly cross-reactive for glycoproteins of plants, insects and molluscs. Therefore, glycan chains are named “cross-reactive carbohydrate determinants” (CCDs). CCDs have been found in allergen extracts of plant origin like tree, weed and grass pollen, vegetables, fruits, seeds, nuts and latex but also in insect venoms, snails and parasites.

More than 20% of all allergic patients produce anti-CCD IgE antibodies. The sensitisation of patients against CCDs probably results from contact with pollen or from insect stings. While usually the occurrence of CCDs in allergen extracts induce no positive results in skin tests, they can lead to positive results or enhanced positive results in in vitro test systems without any pathologically relevance. For these reasons the possible occurrence of CCD-specific IgE antibodies must be considered if in vitro test systems are used.

Profit by the advantages of the CCD-Blocking-Solution:

Improvement of the specificity of the allergy diagnostic according to the recommendations of the German Society for Allergology and Clinical Immunology (Deutsche Gesellschaft für Allergologie und klinische Immunologie)
Inhibition of glycan-specific IgE antibodies – Only peptide-specific IgE antibodies are detected
Just a short preincubation step of 30 Min before running the test
No change in the required serum amount of 300 µl in the AlleisaScreen® test procedure – the serum is mixed with 10% of the CCD-Blocking- Solution. This serum-CCD-mix can be directly used in the test
Further test procedure for the AlleisaScreen® stays unaffected

ad: contact information

About Us

Company details
Company founding
MEDIWISS Analytic GmbH has been developing, manufacturing and selling their own medical products since the foundation in 1999 in Moers, Germany. Our experience in allergologic in vitro diagnostics, developments and technologies has transformed us into a worldwide company that plays an important role in allergy screening diagnostics.

Company meaning
Our guiding objective is to provide a complete system for the allergy screening of specific IgE antibodies and further developed areas such as IgG4 and IgG antibody detection with test panels, hardware, software and customer support. Team members are certified biologists and are regularly trained in the latest medical requirements in the field of allergy and immunology.

Our aim is to simplify professional allergy diagnostics with concomitant sensitivity and specificity. To this end, our products are developed and manufactured to meet the highest standards. Customer suggestions and requirements are taken into consideration since their input ensures the optimal support of customers and distributors around the world.

German quality
Our pursuit of quality is demonstrated by our quality control system ISO 13485:2016.

ad: company